Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Semaglutide (Rybelsus®▼) is the first oral GLP1 receptor agonist (GLP1RA), for the treatment of adults with type 2 diabetes mellitus.
Download the full review below to read more.